The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) will support Wave Life Sciences Ltd's (NASDAQ: WVE) amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) program.
The organizations will support the Company's FOCUS-C9 Phase 1b/2a trial of WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD) and amyotrophic lateral sclerosis (C9-ALS).
The partnership provides an investment from ADDF and AFTD to support the evaluation of fluid biomarkers, functional assessments, and digital biomarkers.
WVE-004 is a stereopure antisense oligonucleotide designed to selectively target transcriptional variants containing a hexanucleotide repeat expansion (G4C2) associated with the C9orf72 gene sparing C9orf72 protein.
G4C2 expansions in C9orf72 are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD.
Price Action: WVE shares closed at $2.15 on Tuesday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.